KIT and hepatocellular carcinoma: Once again, we found that the HCC patients with a high level of TrkC revealed upregulation of CD133, CD117, CK19, and CD90 expression (Figs. 5D, S7A, B) from the TCGA dataset and GSE20140 [19] relative to HCC patients with a low TrkC expression.